Akorn Inc (AKRX) 29.03 $AKRX Technical Analysis on Drugs

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Akorn Inc (AKRX) 29.03 $AKRX

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 12.86 (+0.22), CPRX: 0.88 (-0.01), AKRX: 29.03 (+0.29), PCRX: 38.55 (+0.62)

Akorn Updates Form S-8 Status by Filing Form 10-Q's for First, Second and Third Quarters of 2015
GlobeNewswire - Thu Jun 02, 5:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed quarterly reports on Forms 10-Q with the Securities and Exchange Commission (SEC) for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015. The quarterly financial results that are included in the individual Forms 10-Q were previously filed by the Company in its comprehensive Form 10-K for the fiscal year 2015 that was filed with the SEC on May 10, 2016. The individual Forms 10-Q were filed solely in order to make effective the Company's Registration Statement on Form S-8, on which the Company's securities offered under its employee benefit plan are registered.
AKRX: 29.03 (+0.29)

Akorn to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that management will be presenting at the Jefferies 2016 Healthcare Conference and William Blair 36th Annual Growth Stock Conference in June.
AKRX: 29.03 (+0.29)

SmarTrend Watching for Potential Rebound in Shares of Akorn After 2.24% Loss
Comtex SmarTrend(R) - Thu May 26, 2:05PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $29.37 to a high of $30.51. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $30.27 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 29.03 (+0.29)

Akorn (AKRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:54AM CDT
As of late, it has definitely been a great time to be an investor in Akorn, Inc. (AKRX)
AKRX: 29.03 (+0.29)

Watch for Akorn to Potentially Pullback After Gaining 7.19% Yesterday
Comtex SmarTrend(R) - Tue May 17, 1:24PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $27.90 to a high of $30.39. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $28.19 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 29.03 (+0.29)

Akorn meets 1Q profit forecasts
Automated Insights - Mon May 16, 4:03PM CDT
LAKE FOREST, Ill. (AP) _ Akorn Inc. (AKRX) on Monday reported first-quarter earnings of $41.9 million.
AKRX: 29.03 (+0.29)

SmarTrend Watching for Potential Pullback in Shares of Akorn After 14.34% Gain
Comtex SmarTrend(R) - Tue May 10, 3:26PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $24.43 to a high of $26.81. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $24.43 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 29.03 (+0.29)

Teva's (TEVA) Stock Gains on Q1 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Tue May 10, 6:18AM CDT
2016 is a transition year for Teva (TEVA) as it works on the integration of Actavis Generics and progresses with its branded pipeline.
AKRX: 29.03 (+0.29), TEVA: 51.18 (-0.01), AMPH: 15.92 (+0.33), NVS: 80.09 (+0.38)

Relypsa Soars 67% in Thursday Trading on Buyout Rumors
Arpita Dutt - Zacks Investment Research - Fri Apr 08, 8:50AM CDT
Relypsa (RLYP) shoots up on rumors that the company will be acquired.
AKRX: 29.03 (+0.29), RLYP: 17.09 (-0.08), AZN: 28.98 (+0.28), AMPH: 15.92 (+0.33)

3 Value Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
Image source: Pixabay. While many companies' shares are rising past their fair values now, others are trading at potentially bargain prices. The difficulty with bargain shopping, though, is that you may be understandably hesitant to buy stocks...
AKRX: 29.03 (+0.29), AMCX: 58.63 (+0.14), ICE: 254.94 (+2.94)

3 Beaten-Up Healthcare Stocks: Are They Bargains?
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 22, 9:26PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN. A sharp sell-off in healthcare stocks has left many investors licking their wounds, but other investors might be licking their chops. With many healthcare stocks trading at their lowest valuation in years, the...
JNJ: 116.93 (+0.47), VRX: 21.56 (-0.08), AKRX: 29.03 (+0.29), DEPO: 19.30 (+0.18)

Transocean and Royal Caribbean slump, Wynn and Staples rise
AP - Tue Mar 22, 3:53PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 8.88 (+0.19), ESRX: 76.33 (+0.74), RCL: 77.03 (+0.91), RIG: 11.59 (+0.19), AKRX: 29.03 (+0.29), WYNN: 102.15 (+1.43), ODP: 3.49 (+0.01), MFRM: 34.40 (+0.05), MS: 26.91 (+0.52)

Why Akorn, Inc. Is Soaring 39% Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 22, 12:33PM CDT
Image source: Akorn, Inc. What: Following the release of its preliminary fourth-quarter and full-year financials, shares in Akorn  (NASDAQ: AKRX) are rallying 39.05% at 1:00 p.m. Tuesday.  So what: The mid-sized generic pharmaceutical...
AKRX: 29.03 (+0.29)

Look for Shares of Akorn to Potentially Pullback after Yesterday's 36.93% Rise
Comtex SmarTrend(R) - Tue Mar 22, 11:59AM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $21.78 to a high of $26.26. Yesterday, the shares gained 36.9%, which took the trading range above the 3-day high of $21.23 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 29.03 (+0.29)

Akorn Receives Expected Additional Delinquency Notice From Nasdaq
GlobeNewswire - Mon Mar 07, 6:00AM CST
Akorn, Inc. (Nasdaq:AKRX) today announced that, as expected, it has received a notice from the Nasdaq Listing Qualifications Staff stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its Form 10-K for the year ended December 31, 2015 with the Securities and Exchange Commission (SEC) by February 29, 2016.
AKRX: 29.03 (+0.29)

Akorn Has Returned 20.2% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Fri Feb 05, 10:52AM CST
SmarTrend identified a Downtrend for Akorn (NASDAQ:AKRX) on January 12th, 2016 at $31.33. In approximately 3 weeks, Akorn has returned 20.20% as of today's recent price of $25.00.
AKRX: 29.03 (+0.29)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travelers Turn to Direct Booking Amid Cost Surge

Updated Category News Views 15

Getting Ahead of the Travel Expense Game Rising fees and tighter budgets haven't persuaded holiday travelers to abandon their plans. Instead, they’re sharpening their axes, looking for clearer paths to their vacation goals without slicing off an arm and a leg. With the cost of travel climbing faster than a runaway elevator, folks are getting smart about where their...

Continue Reading
Dan Brown Joins Guidewire: Big Moves in P&C Software

Updated Category News Views 11

Turning the Insurance World on Its Head Just when you think the enterprise software scene is getting predictable, along comes a bit of news to shake things up. Guidewire, a name known in the P&C insurance software world, has roped in a veteran—Dan Brown—who's got more than a quarter-century under his belt shaping product strategies. It’s not just another suit...

Continue Reading
GL1F Crypto: A Breakthrough in On-Chain AI for Crypto

Updated Category News Views 6

The Dawn of On-Chain Machine Learning In a world where crypto folks often tout decentralization like it’s the holy grail, GenesisL1 is throwing open the doors to a new kind of crypto playground with GL1F Crypto. A decentralized on-chain AI studio? Sounds like sci-fi, but here we are—hands on the precipice of democratized machine learning in your browser. A Lab in...

Continue Reading
Event Industry Power 50 Voting Surge Ahead of Close

Updated Category News Views 11

An Unexpected Wave of Enthusiasm in Event Industry The Event Industry Power 50 is getting some serious action this year. Over 3,500 votes have already rolled in, smashing last year's numbers with days still left on the clock. It seems like folks can't wait to see their favorite event powerhouses crowned at this year's gala, which kicks off October 27 in New York City....

Continue Reading
Indiana American Water's PFAS Credits Total $25.5M

Updated Category News Views 7

Indiana American Water Dishes Out Big Buck Refunds Swing by Indiana American Water's latest move, and what do you see? A whopping $25.5 million in PFAS settlement credits being doled out to customers. That's right, this ain't your everyday water utility story—there's real money on the line here. Over four rounds of bill credits since November 2025, customers have seen...

Continue Reading
OMLYCLO Shakes Up U.S. Biologic Market as Key Player

Updated Category News Views 12

Ah, the pharmaceutical game is shifting again, and this time Celltrion USA's putting their chips down with OMLYCLO, the shiny new omalizumab biosimilar. Here we see a product that's not just approved but interchangeable with XOLAIR, making it a front-runner in the allergic and inflammatory conditions battleground. If you're a patient or a provider navigating these murky...

Continue Reading
TRIMAX Poised to Meet AI-Driven Power Challenges

Updated Category News Views 11

TRIMAX's Bold Move into AI-Powered Infrastructure It feels like we're standing on the cusp of a seismic shift, folks. Artificial intelligence isn't just another buzzword anymore—it's a juggernaut reshaping our digital world. TRIMAX Power Systems is gearing up to ride this wave, with its eyes set on capturing a chunk of the booming demand for fast-deployable power...

Continue Reading
Metropolitan Dermatology's Strategic Expansion into Barnegat

Updated Category News Views 12

Diving into Barnegat's Dermatology Landscape Metropolitan Dermatology has taken a strategic step by opening a new location right in the heart of Barnegat, New Jersey. Talk about a win-win for the folks in Ocean County. This isn't just another clinic opening up shop; it's about bringing comprehensive medical and surgical dermatologic care straight to the people who need...

Continue Reading
Aging at Home: The Real Costs and Obstacles Ahead

Updated Category News Views 9

Facing the Realities of Aging In Place Alright, let's talk straight. Everyone dreams of staying home in their twilight years, kicking back in their favorite chair with family nearby. But the harsh truth? That comfort comes with a price tag. According to Northwestern Mutual's 2026 Planning & Progress Study, up to 83% of Boomers+ and most other generations fancy the idea of...

Continue Reading
Palm Beach Royals Boost Pickleball's Popularity Surge

Updated Category News Views 20

A New Era for Pickleball in Palm Beach It might be time to re-evaluate pickleball if you weren't paying attention before. The Palm Beach Royals have wrapped up their first Major League Pickleball season with a bang, marking a pivotal year for the sport. This underdog tale of graft and grit is carving out a new chapter in the world of sport. Record-Breaking Season for MLP...

Continue Reading

Top 5 Most Recently Viewed Articles

Itaú Unibanco to Host Event Introducing Business Developments

Updated Category News Views 205

Itaú Unibanco Event Announcement On September 2, 2025, Itaú Unibanco will host a significant event starting at 8 a.m. EDT, which offers an excellent opportunity for all participants to learn about the latest developments within the company. During this meeting, executives will share valuable insights regarding ongoing efforts and their implications for enhancing user...

Continue Reading
Graphic Packaging Takes Steps to Boost Shareholder Value

Updated Category News Views 98

Graphic Packaging's Commitment to Shareholders Graphic Packaging Holding Company (NYSE: GPK), a leader in sustainable consumer packaging, has made a strong commitment to enhancing shareholder value. The company has issued a statement addressing its ongoing strategy in response to feedback from shareholders, emphasizing its dedication to long-term growth and operational...

Continue Reading
Skanska's Innovative Expansion of Cox Science Center in Florida

Updated Category News Views 175

Skanska's Exciting Project at the Cox Science Center STOCKHOLM – Skanska has embarked on an incredible journey by signing a new contract to expand the Cox Science Center and Aquarium in West Palm Beach, Florida. This impressive project is valued at USD 83M, approximately SEK 820M, signifying a significant investment in scientific education and exploration in the region....

Continue Reading
MicroStrategy Unveils Public Offering for Strike Preferred Stock

Updated Category News Views 214

MicroStrategy Announces Public Offering of Strike Preferred Stock MicroStrategy Incorporated (Nasdaq: MSTR) recently made a noteworthy announcement regarding its plans for a public offering of Series A Perpetual Strike Preferred Stock. With a focus on strengthening its market position and maximizing corporate opportunities, this offering signifies the company’s...

Continue Reading
Sam Bankman-Fried's Letter: Claims, Allegations, and Future Hopes

Updated Category News Views 154

Sam Bankman-Fried's Explosive Revelations About FTX In a recently penned letter, former FTX founder Sam Bankman-Fried expressed a firm belief that FTX was never truly insolvent. He attributed much of the downfall of what he called a "$136 billion enterprise" to mismanagement by attorneys, laying blame for the financial struggles on those who were supposed to provide legal...

Continue Reading